NASDAQ · Biotechnology

PRTA (PRTA) Stock

$8.70 -0.57% NASDAQ: PRTA Healthcare

Valuation

MetricValue
Price$8.70
Market Cap$455.47M
P/E Ratio-6.23
P/B Ratio1.38
P/S Ratio7.37
EPS (TTM)$-1.04
52-Week High$11.80
52-Week Low$5.70
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-40.30%
ROA-13.78%
ROCE-65.84%
Gross Margin46.85%
Operating Margin-2.18%
Net Margin-2.61%
Debt/Equity0.02
Current Ratio7.68

Annual Financials (USD)

Metric20212022202320242025
Revenue$201.0M$54.0M$91.0M$135.0M$10.0M
Operating Profit$72.0M$-132.0M$-191.0M$-155.0M$-185.0M
Net Profit$67.0M$-117.0M$-147.0M$-122.0M$-244.0M
EPS$1.38$-2.47$-2.76$-2.27$-4.53
Op Margin35.9%-244.1%-209.1%-114.4%-1905.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$609.0M$758.0M$696.0M$547.0M$327.0M
Total Liabilities$143.0M$136.0M$135.0M$60.0M$46.0M
Cash$579.0M$710.0M$619.0M$471.0M$308.0M
Borrowings$12.0M$6.0M$12.0M$11.0M$14.0M

Latest News

PRTA Stock Rises Nearly 11% in Six Months: What's Driving It? Zacks · Jul 9, 2026 Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last? Zacks · Jun 12, 2026 Prothena Corp Public Ltd Insider Bought Shares Worth $465,295, According to a Recent SEC Filing MT Newswires · Jun 5, 2026 Prothena Corp Public Ltd Insider Bought Shares Worth $471,300, According to a Recent SEC Filing MT Newswires · Jun 3, 2026 High Insider Ownership Growth Stocks To Watch In May 2026 Simply Wall St. · May 28, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$93.0M$-109.0M$-134.0M$-150.0M$-164.0M
Investing Cash Flow$-1.0M$-1.0M$-6.0M$-1.0M$0
Financing Cash Flow$16.0M$18.0M$22.0M$2.0M$0
Net Cash Flow$282.0M$132.0M$-92.0M$-149.0M$-164.0M
Free Cash Flow$92.0M$-109.0M$-137.0M$-150.0M$-164.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-1.19
FCF Yield-19.07%
Quick Ratio10.43
Interest Coverage—
Return 1Y26.18%
Return 3Y-86.83%
Return 5Y-83.31%

Ownership

Insiders Held20.18%
Institutions Held90.77%
Institutions Float Held113.73%
Institutional HolderSharesReport Date
FMR, LLC7,551,2182026-03-31
Rubric Capital Management LP5,000,0002026-03-31
Blackrock Inc.4,644,1602026-03-31
State Street Corporation1,938,4982026-03-31
Shaw D.E. & Co., Inc.1,763,3472026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCYCBicycle Therapeutics plc $4.22 +0.24% -1.34 $292.84M 0.00%
CRVS $13.31 +3.02% -23.00 $1.12B 0.00%
FDMT $10.09 -0.88% -3.47 $527.47M 0.00%
GOSSGossamer Bio, Inc. $0.19 +38.24% -0.17 $44.10M 0.00%
KALV $27.00 +0.00% -8.28 $1.44B 0.00%

About PRTA

PRTA is led by CEO Gene G. Kinney, employs 163 people, headquartered in US, publicly traded since 2012.

PRTA stock trades at $8.70 with a market capitalization of $455.47M. The stock is valued at a price-to-earnings (P/E) ratio of -6.23, price-to-book of 1.38, price-to-sales of 7.37. Over the past 52 weeks the stock has ranged between $5.70 and $11.80, and currently trades 26.3% below its 52-week high.

On profitability, PRTA generates a return on equity (ROE) of -40.30%, return on capital employed of -65.84%, an operating margin of -2.18%, a net profit margin of -2.61%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides